Joined ATOM: 2024
Favorite part about working with ATOM:
“Equity of access to a globally accepted standard of care has been a great interest of mine. We are seeing disease modifying therapies come to market at considerable cost and administration burden which often puts these therapies out of reach for patients. Being able to help bring trials to parts of the world that would not otherwise have access and ensure sites are resourced in terms of manpower and knowledge around clinical trials and standards of care is deeply satisfying. My role on a more global scale has allowed me to have a greater impact in helping to improve the equity of access to disease modifying therapies and a globally accepted standard of care. I enjoy the challenge of always striving to improve this.”
Areas of research that excite me the most:
“The end product. The culmination of years of relentless work from the lab to the clinic, resulting in access to life-changing, disease-modifying therapies and improved standards of care and quality of life for our patients and those who love them. This is my why.”
Biggest challenge for research in the next five years:
“Building clinical trial capacity in areas of the world that don’t currently have access. I am very passionate about access to clinical trials, disease modifying therapies and globally accepted standards of care, and I do not believe your socioeconomic background should dictate your access to any of these. Over the past few years, I have seen increasing investment into growing clinical trial capacity in regions such as Southeast Asia, Mainland China, India and Africa, and I hope this will continue. You have to build things from the ground up, so I look forward to doing more standards of care workshops and supporting my colleagues across APAC and Subcontinent.”
Fun fact:
“I am a crazy plant lady. I love rare and exotic plants, and my house and garden are full of fabulous green girls and boys. They make me happy.”
